Ocular Therapeutix Inc. (OCUL)

3.50
0.12 3.30
NASDAQ : Health Technology
Prev Close 3.62
Open 3.62
Day Low/High 3.39 / 3.62
52 Wk Low/High 2.35 / 6.88
Volume 234.62K
Avg Volume 521.00K
Exchange NASDAQ
Shares Outstanding 47.20M
Market Cap 162.35M
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ocular Therapeutix™ To Present At The 2019 Cantor Global Healthcare Conference

Ocular Therapeutix™ To Present At The 2019 Cantor Global Healthcare Conference

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Donald Notman, Chief Financial Officer...

Ocular Therapeutix™ Announces First Patient Dosed In Phase 3 Clinical Trial Of DEXTENZA® For The Treatment Of Allergic Conjunctivitis

Ocular Therapeutix™ Announces First Patient Dosed In Phase 3 Clinical Trial Of DEXTENZA® For The Treatment Of Allergic Conjunctivitis

Ocular Therapeutix ™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has dosed the first patients in...

2 Stocks on My Radar in a Low-Energy Market

2 Stocks on My Radar in a Low-Energy Market

Flat markets tend to produce favorable technical setups, but this one may put us to sleep while we wait for further developments.

Ocular Therapeutix™ To Present At The 2019 Wells Fargo Healthcare Conference

Ocular Therapeutix™ To Present At The 2019 Wells Fargo Healthcare Conference

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief...

OCUL Makes Notable Cross Below Critical Moving Average

OCUL Makes Notable Cross Below Critical Moving Average

In trading on Monday, shares of Ocular Therapeutix Inc crossed below their 200 day moving average of $4.28, changing hands as low as $4.26 per share. Ocular Therapeutix Inc shares are currently trading off about 3.7% on the day.

OCUL: Insiders Vs. Shorts

OCUL: Insiders Vs. Shorts

The most recent short interest data was recently released for the 04/15/2019 settlement date, and Ocular Therapeutix Inc is one of the most shorted stocks of the Russell 3000, based on 16.15 "days to cover" versus the median component at 5.30. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Ocular Therapeutix™ Reports Second Quarter 2019 Financial Results And Business Update

Ocular Therapeutix™ Reports Second Quarter 2019 Financial Results And Business Update

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the second quarter...

Ocular Therapeutix™ To Report Second Quarter 2019 Financial Results

Ocular Therapeutix™ To Report Second Quarter 2019 Financial Results

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report second quarter ended...

2 Promising $5 Biotech Stocks to Consider on Recent News

2 Promising $5 Biotech Stocks to Consider on Recent News

Jounce Therapeutics and Ocular Therapeutix each provided investors with positive news morsels last week.

Ocular Therapeutix™ Announces Early Assignment Of Permanent And Specific J-Code (J1096) For DEXTENZA® (dexamethasone Ophthalmic Insert) 0.4mg By The Centers For Medicare And Medicaid Services

Ocular Therapeutix™ Announces Early Assignment Of Permanent And Specific J-Code (J1096) For DEXTENZA® (dexamethasone Ophthalmic Insert) 0.4mg By The Centers For Medicare And Medicaid Services

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the Centers for Medicare and Medicaid...

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the Company entered into an...

Ocular Therapeutix™ Announces Christopher White As Senior Vice President, Head Of Business And Corporate Development

Ocular Therapeutix™ Announces Christopher White As Senior Vice President, Head Of Business And Corporate Development

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Christopher White as...

Ocular Therapeutix™ Announces Patricia Kitchen As Chief Operations Officer

Ocular Therapeutix™ Announces Patricia Kitchen As Chief Operations Officer

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Patricia Kitchen as...

Ocular Therapeutix™ Announces Commercial Launch Of DEXTENZA® (dexamethasone Intracanalicular Insert) 0.4 Mg For Ophthalmic Use In The United States

Ocular Therapeutix™ Announces Commercial Launch Of DEXTENZA® (dexamethasone Intracanalicular Insert) 0.4 Mg For Ophthalmic Use In The United States

Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the commercial launch in the United States...

Bitcoin: A Trading Opportunity in an Asset With No Intrinsic Value

Bitcoin: A Trading Opportunity in an Asset With No Intrinsic Value

Its price is determined by emotion more than anything else.

First Week Of August 16th Options Trading For Ocular Therapeutix (OCUL)

First Week Of August 16th Options Trading For Ocular Therapeutix (OCUL)

Investors in Ocular Therapeutix Inc saw new options begin trading this week, for the August 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OCUL options chain for the new August 16th contracts and identified the following call contract of particular interest.

A Summer Friday Has Me Hunting for New Stock Ideas

A Summer Friday Has Me Hunting for New Stock Ideas

The important thing to remember on days like this is to not read too much into the action.

Ocular Therapeutix™ Announces FDA Approval Of Supplemental New Drug Application (sNDA) For DEXTENZA® (0.4 Dexamethasone Intracanalicular Insert For Ophthalmic Use) For The Treatment Of Ocular Inflammation Following Ophthalmic Surgery

Ocular Therapeutix™ Announces FDA Approval Of Supplemental New Drug Application (sNDA) For DEXTENZA® (0.4 Dexamethasone Intracanalicular Insert For Ophthalmic Use) For The Treatment Of Ocular Inflammation Following Ophthalmic Surgery

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the U.

Ocular Therapeutix™ To Present At Three Upcoming Investor Conferences

Ocular Therapeutix™ To Present At Three Upcoming Investor Conferences

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present and host investor...

Ocular Therapeutix™ Announces Receipt Of C-Code And Pass-Through Payment Status For DEXTENZA®

Ocular Therapeutix™ Announces Receipt Of C-Code And Pass-Through Payment Status For DEXTENZA®

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the Centers for Medicare and Medicaid...

Ocular Therapeutix™ Announces Topline Results Of Phase 3 Clinical Trial Of OTX-TP For The Treatment Of Glaucoma

Ocular Therapeutix™ Announces Topline Results Of Phase 3 Clinical Trial Of OTX-TP For The Treatment Of Glaucoma

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced topline results from the first pivotal...

OCUL: Insiders Vs. Shorts

OCUL: Insiders Vs. Shorts

The most recent short interest data was recently released for the 04/15/2019 settlement date, and Ocular Therapeutix Inc is one of the most shorted stocks of the Russell 3000, based on 16.15 "days to cover" versus the median component at 5.30. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Ocular Therapeutix™ Reports First Quarter 2019 Financial Results And Business Update

Ocular Therapeutix™ Reports First Quarter 2019 Financial Results And Business Update

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the first quarter...

Ocular Therapeutix™ To Report First Quarter 2019 Financial Results

Ocular Therapeutix™ To Report First Quarter 2019 Financial Results

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report first quarter ended...

Ocular Therapeutix Announces DEXTENZA® (dexamethasone Ophthalmic Insert) Recommended For Unique J-Code By CMS

Ocular Therapeutix Announces DEXTENZA® (dexamethasone Ophthalmic Insert) Recommended For Unique J-Code By CMS

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that the Centers for Medicare and Medicaid Services...

First Week Of December 20th Options Trading For Ocular Therapeutix (OCUL)

First Week Of December 20th Options Trading For Ocular Therapeutix (OCUL)

Investors in Ocular Therapeutix Inc saw new options begin trading this week, for the December 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Ocular Therapeutix, Inc. Settles Litigation With Mati Therapeutics, Inc.

Ocular Therapeutix, Inc. Settles Litigation With Mati Therapeutics, Inc.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has settled litigation with Mati...

Ocular Therapeutix™ To Present New Data At The Association For Research In Vision And Ophthalmology (ARVO) Annual Meeting And At The American Society Of Cataract And Refractive Surgery (ASCRS) Symposium

Ocular Therapeutix™ To Present New Data At The Association For Research In Vision And Ophthalmology (ARVO) Annual Meeting And At The American Society Of Cataract And Refractive Surgery (ASCRS) Symposium

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced abstracts from its clinical and preclinical...

TheStreet Quant Rating: D- (Sell)